Table 1 Effect of tubacin and/or 17-AAG... | American Society of Hematology

Table 1

Effect of tubacin and/or 17-AAG on viability of primary AML and CML-BC (blast crisis) blasts and normal CD34⁺ progenitor cells

	Control	3 μM tubacin	1 μM 17-AAG	3 μM 17-AAG	3 μM tubacin plus 1 μM 17-AAG	3 μM tubacin plus 3 μM 17-AAG
AML 1	7.6	12.7	26.6	31.3	37.3	47.4
AML 2*	9.4	13.4	36.8	49.5	52.0	59.6
AML 3*	2.7	8.1	24.3	39.4	31.5	47.8
CML 1	0.0	2.1	13.2	27.0	35.8	37.3
CML 2*	4.5	11.3	19.7	24.0	29.3	36.8
CML 3*	4.8	12.6	33.2	44.2	46.9	53.7
CD34⁺ normal*	7.9 ± 1.8	13.8 ± 0.4	16.5 ± 0.9	20.3 ± 0.9	21.2 ± 2.2	16.4 ± 2.5

	Control	3 μM tubacin	1 μM 17-AAG	3 μM 17-AAG	3 μM tubacin plus 1 μM 17-AAG	3 μM tubacin plus 3 μM 17-AAG
AML 1	7.6	12.7	26.6	31.3	37.3	47.4
AML 2*	9.4	13.4	36.8	49.5	52.0	59.6
AML 3*	2.7	8.1	24.3	39.4	31.5	47.8
CML 1	0.0	2.1	13.2	27.0	35.8	37.3
CML 2*	4.5	11.3	19.7	24.0	29.3	36.8
CML 3*	4.8	12.6	33.2	44.2	46.9	53.7
CD34⁺ normal*	7.9 ± 1.8	13.8 ± 0.4	16.5 ± 0.9	20.3 ± 0.9	21.2 ± 2.2	16.4 ± 2.5

Data are percentages of dead cells.

CML and AML samples were grown on the human bone marrow–derived HS-5 stromal cells.

CD34⁺ normal values are means plus and minus SD.